Crry silencing alleviates Alzheimer's disease injury by regulating neuroinflammatory cytokines and the complement

Xi-Chen Zhu1, Lu Liu2, Wen-Zhuo Dai2

  • 1Department of Neurology, Wuxi No. 2 People's Hospital of Nanjing Medical University; Department of Neurology, Wuxi No. 2 People's Hospital, Affiliated Wuxi Clinical College of Nantong University, Wuxi, Jiangsu Province, China.

Insights

Silencing the mouse Cr1-related protein Y (Crry) in a mouse model of tau pathology reduced tau phosphorylation and neuroinflammation. This intervention improved cognitive function and reduced neuronal apoptosis, suggesting Crry as a therapeutic target for tauopathies.

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Complement component 1 (CR1) is linked to Alzheimer's disease susceptibility and tau protein phosphorylation.
  • The precise function of CR1 in tau protein-associated neurodegenerative diseases remains unclear.
  • The mouse Cr1-related protein Y (Crry) is expressed in microglia.

Purpose of the Study:

  • To investigate the role of Crry in tau protein phosphorylation and associated neuroinflammation.
  • To evaluate the therapeutic potential of Crry silencing in a mouse model of tau pathology.

Main Methods:

  • Utilized P301S mice, a model for tau pathology.
  • Employed lentivirus-transfected short hairpin RNA for Crry gene silencing.
  • Assessed tau phosphorylation, kinase activity, neuronal apoptosis, cognitive function, and neuroinflammatory markers.

Main Results:

  • Crry expression was elevated in the hippocampus and cortex of P301S mice.
  • Crry silencing significantly reduced tau phosphorylation and the activity of tau kinases (GSK-3β and CDK5).
  • Crry silencing decreased neuroinflammation, complement component levels, neuronal apoptosis, and rescued cognitive impairment in P301S mice.

Conclusions:

  • Crry plays a significant role in tau protein phosphorylation and neuroinflammation in the P301S mouse model.
  • Crry silencing ameliorates tau pathology, neuroinflammation, and cognitive deficits.
  • Targeting Crry may offer a novel therapeutic strategy for tauopathies.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
285
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
719
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.2K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
228
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
1.3K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.5K